EGF-IL-18 fusion protein as a potential anti-tumor reagent by induction of immune response and apoptosis in cancer cells

Jianxin Lu, Y. Peng, Z. J. Zheng, J. H. Pan, Yangde Zhang, Yidong Bai

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

We report here the generation and characterization of EGF-IL-18 fusion protein as an anti-tumor reagent. The epidermal growth factor (EGF) and interleukin-18 (IL-18) fusion protein was shown to induce interferon-γ (IFNγ) expression and secretion in KG-1 cells, and to promote PBMNC proliferation. It also stimulated activation of CD4+ T cells, and increased other immune responses. Moreover, EGF-IL-18 could induce significant tumor regression in SMMC-7721-xenografted Balb/c nude mice when administered together with peritumoral injection of X-ray-irradiated NK-92 cells, and this regression is associated with arresting of the tumor cells in G1 phase and induction of apoptosis.

Original languageEnglish (US)
Pages (from-to)187-197
Number of pages11
JournalCancer Letters
Volume260
Issue number1-2
DOIs
StatePublished - Feb 18 2008

Keywords

  • Anti-cancer
  • Apoptosis
  • Epidermal growth factor (EGF)
  • Fusion protein
  • Interleukin-18 (IL-18)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'EGF-IL-18 fusion protein as a potential anti-tumor reagent by induction of immune response and apoptosis in cancer cells'. Together they form a unique fingerprint.

Cite this